Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020
TAIPEI, April 30, 2024 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia. The Phase 1 clinical trial is a randomized, double-blind, placebo-controlled, single-center, single, and multiple ascending oral dose study to evaluate the safety, tolerability, and pharmacokinetics of FP-020 in healthy … Read more
